Digoxin’s narrow therapeutic window and individual patient variability necessitate careful monitoring and consideration in clinical practice.

Changes to blood-based biomarkers can be detected before Alzheimer’s symptoms appear, potentially allowing for earlier intervention and more targeted treatment approaches.

Actigraphy devices revealed significant improvements in sleep patterns with nighttime levodopa use, despite patients not perceiving these changes subjectively.

Recent studies have identified a range of chemical compounds released by face masks, including microplastics, volatile organic compounds, and plasticizers, prompting a closer examination of potential cumulative exposure risks.

Twice-yearly azithromycin distribution to children aged 1-59 months reduced all-cause mortality by 14% compared to placebo, even in communities with lower baseline mortality rates and ongoing malaria prevention efforts.

Regular high caffeine intake could disturb the parasympathetic system, potentially leading to elevated blood pressure and heart rates in otherwise healthy individuals.